Yeah, the SOONer the BETTER! I've read of patients still alive in trials, and of further data analysis, relating to my biggest concern, which is the science. I trust all that has been proven already, or otherwise turns out to be even better than initially reported. That would be to Soon's advantage, although it would still be a BIG deal for CYTR in M&R $$ and further development of LADR.
Whether or not the R/S passes or even if they go through with it or the SHM remains to be seen. BUT, I honestly believe CYTR is greatly undervalued at the moment to the point I'm trying to sell some other "non-performers" so I can p/u more shares of this one before the 27th. lol! I think CYTR has the best chance of performing in the near term. One thing's for sure, time will tell.
All IMO. GLTY & CYTR!